AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02176304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depomedrol
Description: Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
Study NCT02176304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252161
Description: 10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
Study NCT01616277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, Subcutaneous injection, single dose
Study NCT03928860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT session
Description: Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
Study NCT00925145 — intervention group
Intervention type: PROCEDURE
Intervention: Single Incision Laparoscopic Appendectomy
Study NCT03770195 — intervention group
Intervention type: DEVICE
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Study NCT01646801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMB Balloon Catheter
Description: patients treated by the NMB's Drug Ejecting Balloon
Study NCT01877590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Study NCT01226706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
Study NCT01226706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
Study NCT01165099 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
Study NCT01165099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single intravenous dose
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Given intravenously over 40 minutes
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (saline)
Description: Given intravenously over 40 minutes
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single intravenous dose given over 40 minutes
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Given intravenously over 40 minutes
Study NCT02317341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam(placebo)
Description: Given intravenously over 40 minutes
Study NCT00759746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFM+ Low Dose
Description: The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
Study NCT02472171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and sunflower oil
Description: High saturated fat meal with a blueberry flavored shake and sunflower oil
Study NCT00759746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance Education
Description: The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
Study NCT00759746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFM+ High Dose
Description: The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
Study NCT03385174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbon monoxide
Description: Carbon monoxide inhalation
Study NCT02472171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil
Study NCT02808351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Study NCT01514149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC Injection
Description: CJC-1134-PC administered weekly by subcutaneous injection
Study NCT03025893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib, 300 mg administered orally in a weekly schedule.
Study NCT03025893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
Study NCT01949298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement
Study NCT02472171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA
Study NCT02254161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Tablet
Study NCT02254161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 healthy elderly
Description: Tablet
Study NCT02254161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 Healthy young
Description: Tablet
Study NCT01452711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
Study NCT01452711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
Study NCT01452711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT01452711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24G intravenous route for Lumbar Sympathetic Block (LSB):
Description: Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24G intravenous route for Lumbar Sympathetic Block (LSB):
Description: Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
Study NCT02737527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 15-cm Chiba needle for Lumbar Sympathetic Block (LSB)
Description: The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
Study NCT02737527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15-cm Chiba needle for Lumbar Sympathetic Block (LSB)
Description: The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
Study NCT02737527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound for Lumbar Sympathetic Block (LSB)
Description: Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
Study NCT02737527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscope for Lumbar Sympathetic Block (LSB)
Description: Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
Study NCT02737527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml of 0.25% levobupivacaine injection for LSB
Description: After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
Study NCT02737527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% levobupivacaine injection for LSB
Description: After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB)
Description: Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB)
Description: Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postprocedure care for LSB
Description: Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
Study NCT02737527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprocedure care for LSB
Description: Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
Study NCT01616277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, repeat dose
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study NCT02804490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional white maize
Description: Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
Study NCT02804490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoid biofortified maize
Description: Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
Study NCT02804490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preformed vitamin A fortified maize
Description: Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
Study NCT03531814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS^TM)
Description: A computerized method of tracking the dates and times of a pill bottle being opened.
Study NCT03531814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
Study NCT01849315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AKIDS II
Description: Physically active intervention
Study NCT01849315 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AKIDS II
Description: Physically active intervention
Study NCT03375931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
Study NCT03375931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-prayer
Description: If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
Study NCT01913847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral sildenafil 20 mg TID for 12 weeks
Study NCT01913847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo TID for 12 weeks
Study NCT01673646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 > ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
Study NCT01485796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Infusion (Human), 10%
Description: Subcutaneous administration will be used in Study Epochs 1 and 2.
Study NCT01485796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase
Description: rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment
Description: Once daily application 6 days a week for 3 weeks
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betnovat® ointment
Description: Once daily application 6 days a week for 3 weeks
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosalic ointment
Description: Once daily application 6 days a week for 3 weeks
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermovat ointment
Description: Once daily application 6 days a week for 3 weeks
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocon ointment
Description: Once daily application 6 days a week for 3 weeks
Study NCT00845481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment vehicle
Description: Once daily application 6 days a week for 3 weeks
Study NCT01514149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Weekly placebo for CJC-1134-PC Injection
Description: Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
Study NCT02252042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
Study NCT02252042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
Study NCT02252042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV on Day 1 of each 3- week cycle
Study NCT02252042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
Study NCT02168400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Study NCT02168400 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Study NCT04456751 — intervention group
Intervention type: OTHER
Intervention: Redo op
Description: Patients with a redo operation